FourLight shows 1st CDK4i Atirmociclib after CDK4/6i shows significant improvement in mPFS 9.4 vs 6.6 mos HR=0.60

Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·2026-10-24 15:06· 22 小时前评分70

正文 · 原文

FourLight shows 1st CDK4i Atirmociclib after CDK4/6i shows significant improvement in mPFS 9.4 vs 6.6 mos HR=0.60
notable AE neutropenia

#ESMO26 @OncoAlert

184 浏览 · 4 赞 · 4 转发 · 1 回复

会议摘要

1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)

https://esmocongress.esmo.org

帖内回复

Ziad Storyteller@AIZiadSaliba
@DrSGraff @OncoAlert @antgiorda Slides show the atirmociclib arm carried more liver mets (44% vs 29%) and more ESR1 alterations, yet still delivered HR 0.60. I'd want blinded independent review before calling it, given the investigator-assessed primary endpoint. #ESMO26

来源：Stephanie Graff, MD, FACP, FASCO · x.com